T-705 Efficacy and Reduced Toxicity Suggests an Alternative to Ribavirin Therapy for Arenaviral Disease
Author Information
Author(s): Gowen Brian B., Smee Donald F., Wong Min-Hui, Hall Jeffery O., Jung Kie-Hoon, Bailey Kevin W., Stevens John R., Furuta Yousuke, Morrey John D.
Primary Institution: Institute for Antiviral Research, Logan, Utah, United States of America
Hypothesis
Can T-705 provide effective treatment for late-stage arenaviral hemorrhagic fever compared to ribavirin?
Conclusion
T-705 is as effective as ribavirin but less toxic, suggesting it could be a better treatment option for severe arenaviral infections.
Supporting Evidence
- T-705 provided significant protection against lethal arenaviral infection in hamsters.
- T-705-treated hamsters maintained their weight better than those treated with ribavirin.
- Combination therapy with T-705 and ribavirin showed no added benefit.
- Pharmacokinetic data indicated reduced plasma T-705 levels during late-stage disease.
Takeaway
This study found that a new drug called T-705 works well to help sick hamsters recover from a dangerous virus, and it doesn't make them as sick as an older medicine.
Methodology
Hamsters were infected with Pichinde virus and treated with T-705 or ribavirin, with their health and viral loads monitored over time.
Potential Biases
Potential bias in the selection of treatment dosages and timing.
Limitations
The study was conducted in hamsters, which may not fully represent human responses to treatment.
Participant Demographics
Female 7–8 week-old Syrian hamsters.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website